A Review On CRISPR-Cas9 Gene Therapy: Revolutionizing the Treatment of Genetic Disorders

Kailash Kumar[1], Kali Kumari[2], Jatin Upadhyay[3], Dr. Arfa Khan[4*], Dr.Ragvendra Singh Bhadauria[5]
[1-2-3]Student B.Pharm, Sunrise College of Pharmacy, Umarada, Udaipur
[4]Assistant Professor, Sunrise College of Pharmacy, Umarada, Udaipur
[5]Principal, Sunrise College Of Pharmacy, Umarada, Udaipur

***Abstract*—CRISPR-Cas9 has emerged as a groundbreaking genome-editing technology that enables targeted, efficient, and cost-effective modification of genetic material. Originating from a natural bacterial defense system, CRISPR-Cas9 has significantly advanced beyond previous tools such as Zinc Finger Nucleases (ZFNs) and Transcription Activator-Like Effector Nucleases (TALENs), owing to its simplicity, precision, and scalability. The system uses a guide RNA (gRNA) to direct the Cas9 enzyme to specific DNA sequences, where it induces double-strand breaks. These breaks are repaired by cellular mechanisms—non-homologous end joining (NHEJ) or homology-directed repair (HDR) allowing for gene disruption, correction, or insertion. This review explores the mechanism of CRISPR-Cas9 and highlights its therapeutic applications in various genetic disorders, including sickle cell anemia, cystic fibrosis, Huntington's disease, and Leber congenital amaurosis. In several of these conditions, CRISPR-based therapies have shown promising results in clinical and preclinical studies, leading to breakthroughs such as the FDA-approved Casgevy for sickle cell disease. Emerging technologies like base and prime editing enhance precision by enabling nucleotide-level changes without inducing double-strand breaks. Despite its potential, CRISPR faces significant challenges including off-target effects, delivery limitations, and immune responses. Ethical concerns, particularly regarding germline editing and equitable access, also demand careful regulation and societal dialogue.**

***Index Terms*—CRISPR-Cas9, gene editing, genetic disorders, base editing, prime editing, therapeutic applications, off-target effects, ethical considerations.**

1. INTRODUCTION

1.1 Genetic Disorders: An Overview

Genetic disorders result from mutations or variations in the DNA sequences that impair the normal functioning of genes. These mutations may be inherited from parents or acquired somatically.[1, 2] They disrupt the production or function of proteins critical for cellular processes, resulting in disease phenotypes. Genetic diseases are broadly categorized as:

- Monogenic diseases: Caused by mutations in a single gene, e.g., sickle cell anemia.[3]
- Complex diseases: Involve multiple genes and environmental factors, such as cancer and Alzheimer's disease.[4]
- Traditional therapies often manage symptoms but do not address underlying genetic causes, underscoring the need for precise molecular interventions.[5]



Figure 1: CRISPR-Cas9 in Genetic Disorders[5]

1.2 Evolution of Gene Editing Technologies

Historically, gene editing was limited by the complexity of manipulating DNA sequences. Technologies like ZFNs and TALENs allowed site-specific cuts but required complex protein engineering. The discovery of the CRISPR-Cas9 system, adapted from bacterial immunity, revolutionized genome editing due to its RNA-guided targeting and ease of use[6, 7]

1.2.1 Zinc Finger Nucleases (ZFNs)

- ZFNs are engineered proteins that consist of:
- DNA-Binding Domain: Zinc finger motifs recognize and bind to specific DNA sequences.
- FokI Nuclease Domain: A non-specific nuclease that cleaves DNA when two ZFNs bind adjacently, forming a dimmer.
- ZFNs rely on precise protein engineering to target specific sequences, making their design complex and time-consuming[8.]

1.2.2 Transcription Activator-Like Effectors Nucleases (TALENs)

TALENs are similar to ZFNs but use transcription activator-like effectors (TALEs) as their DNA-binding domains. These domains recognize specific DNA sequences, and the FokI nuclease induces DSBs. TALENs offer greater specificity and modularity compared to ZFNs[9, 10]

1.2.3 Comparison with ZFNs and TALENs

S. NO	FEATURE	ZFNs	TALENs	CRISPR-Cas9
1.	Target recognition	Engineered proteins	TALE repeats	RNA-guided
2.	Ease of design	Complex, protein engineering	Moderate	Simple, guide RNA synthesis
3.	Cost	High	Moderate	Low
4.	Multiplexing	Difficult	Moderate	Easy
5.	Off-target risk	Moderate	Moderate	Reduced in newer variants[11,12]

2. MECHANISM OF CRISPR-CAS9

The CRISPR-Cas9 system works as a sharp tool of DNA targeting and editing and has revolutionized the field of genetic engineering. At its core, the system relies on two key components: the guide RNA (gRNA) and the Cas9 endonuclease. Having summarized the above, the following are the findings of the research – They must be designed to be complementary to a particular genomic region in order for the gRNA to direct Cas9 to the preferred focuses within the genome. This targetable programmability is much more advantageous than previous Gene editing tools that include ZFNs and TALENs that needed rigorous protein engineering on the target site.[12, 17]

Once it finds its specific target, the Cas9 protein causes the DNA to cleave at one or two sites to produce a double-strand break. This DSB triggers one of two cellular repair pathways:

1. Non-Homologous End Joining (NHEJ): This partially incorrect repair frequently results in small insertions and/or deletions (indels) at the break site causing a gene disruption. Although useful in gene knockout experiments, NHEJ is very random and therefore can lead to secondary undesired genetic modifications

2. Homology-Directed Repair (HDR): HDR uses a similar DNA sequence in order to repair the break with the same level of precision as in the insertion or the correction of genetic information. Nonetheless, HDR is comparatively slower to NHEJ, and occurs mainly in the dividing cells and hence, has some restriction in terms of application in few therapeutic strategies.



Figure 2: Different b/w NHEJ & HDR

2.1 Gene Editing Workflow

- Guide RNA (gRNA) Design: Synthesized to complement target DNA sequence.
- Cas9 Binding and Cleavage: Cas9-gRNA complex binds the DNA adjacent to PAM (Protospacer Adjacent Motif) sequences and introduces double-strand breaks (DSBs[6] .
- DNA Repair Pathways:
- Non-Homologous End Joining (NHEJ): Fast, error-prone, often causing insertions/deletions (indels), useful for gene knockouts.
- Homology-Directed Repair (HDR): Precise repair using a homologous template, enabling gene correction or insertion.

3. THERAPEUTIC APPLICATIONS

3.1 Pathophysiology of Genetic Disorders

Genetic mutations disrupt gene function by altering protein coding or regulation. For example, point mutations can change amino acids, affecting protein folding or function; deletions or insertions can cause frameshifts leading to truncated proteins.

3.2 CRISPR-Cas9 Targeting Strategies

- Gene Disruption via NHEJ: Introducing indels to knockout genes causing disease.
- Gene Correction via HDR: Precise replacement or insertion using a donor template.
- Base Editing: Directly converts one nucleotide to another without DSBs.
- Prime Editing: Uses a Cas9 nickase fused with reverse transcriptase to perform versatile edits without DSBs.

3.3 Case Studies of CRISPR-Cas9

3.3.1 Sickle Cell Anemia (SCA)

Sickle Cell Anemia is a monogenic disorder caused by a single point mutation (Glu6Val) in the HBB gene, resulting in the production of abnormal hemoglobin S (HbS). This alteration leads to sickling of red blood cells under hypoxic conditions, causing hemolysis, vaso-occlusion, and severe pain crises. CRISPR-Cas9-based gene therapy for SCA focuses on reactivating the expression of fetal hemoglobin (HbF), which can compensate for the dysfunctional adult hemoglobin. This is achieved by disrupting the BCL11A erythroid-specific enhancer in autologous hematopoietic stem and progenitor cells (HSPCs), thereby re-inducing HbF production. Clinical trials such as CLIMB-121 have shown remarkable clinical efficacy, including transfusion independence and significant symptom relief. The U.S. FDA approval of Casgevy™ (exa-cel), a CRISPR-based therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics, marks a historic milestone in the treatment of SCA.

3.3.2 Cystic Fibrosis (CF)

Cystic Fibrosis is an autosomal recessive disorder caused by mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, impairing chloride ion transport and leading to thickened mucus secretions, particularly in the lungs and digestive system. The most common mutation, F508del, results in misfolded CFTR protein and dysfunctional chloride channels. CRISPR-Cas9 has been used successfully to correct this mutation in patient-derived intestinal organoids, demonstrating restoration of CFTR function. Additionally, preclinical animal models have shown positive results, offering proof-of-concept for future therapies. However, significant challenges remain, particularly in achieving efficient in vivo delivery to the affected epithelial tissues and ensuring long-term therapeutic expression without triggering immune responses.

3.3.3 Huntington’s Disease (HD)

Huntington’s Disease is a progressive neurodegenerative disorder caused by an abnormal expansion of CAG trinucleotide repeats in the HTT gene, leading to the production of mutant huntingtin protein (mHTT) that aggregates in neurons. This results in motor dysfunction, cognitive decline, and psychiatric symptoms. CRISPR-Cas9-based approaches are being explored to either excise the expanded CAG repeats or selectively silence the mutant allele while preserving the wild-type allele. Preclinical studies using transgenic mouse models of HD have demonstrated improved motor performance, reduced aggregate formation, and decreased neuro-degeneration. These results highlight the potential of CRISPR-based interventions for modifying the course of this otherwise untreatable condition.

3.3.4 Leber Congenital Amaurosis (LCA)

Leber Congenital Amaurosis (LCA) is a rare inherited retinal dystrophy that leads to severe vision loss or blindness at birth or in early childhood. One of the most common genetic causes of LCA is a mutation in the CEP290 gene, which disrupts the function of photoreceptor cells in the retina.A promising therapeutic approach utilizes EDIT-101, an in vivo CRISPR-Cas9 gene-editing therapy developed by Editas Medicine. This therapy is administered via adeno-associated virus (AAV) vectors directly into the subretinal space, enabling targeted editing of the CEP290 gene mutation (specifically the c.2991+1655A>G intronic variant) in retinal cells.Early-phase clinical trials have reported encouraging results, including improved light perception and visual function in some treated patients, with a favorable safety profile. These findings represent a significant advancement in applying CRISPR technology for treating genetic disorders directly within the human body, especially in tissues like the retina where localized delivery is feasible.

4. APPLICATIONS OF CRISPR-CAS9 IN GENETIC DISORDERS

The case studies discussed above highlight the broad and transformative potential of CRISPR-Cas9 gene editing in addressing various genetic diseases. The key therapeutic applications are as follows:

1. Restoration of Functional Protein Expression
- In Cystic Fibrosis, CRISPR-Cas9 corrects the F508del mutation in the CFTR gene, restoring normal chloride ion transport and protein function in epithelial cells.
2. Reactivation of Fetal Genes to Compensate for Mutations
- In Sickle Cell Anemia, CRISPR is used to disrupt the BCL11A gene enhancer, thereby reactivating fetal hemoglobin (HbF) to compensate for defective adult hemoglobin (HbS).
3. Selective Silencing or Deletion of Toxic Genes
- In Huntington’s Disease, CRISPR-Cas9 enables the excision of expanded CAG repeats or silencing of the mutant HTT allele, reducing toxic protein accumulation and neurodegeneration.
4. In Vivo Gene Editing in Targeted Tissues
- In Leber Congenital Amaurosis, EDIT-101 delivers CRISPR components directly to the retina via AAV vectors, enabling localized gene correction without systemic effects—demonstrating the feasibility of in vivo gene editing in sensitive organs.
5. Development of Personalized and Disease-Specific Therapies
- Each case illustrates how CRISPR can be tailored to correct disease-specific mutations, opening avenues for personalized medicine and targeted therapeutic interventions.
6. Long-Term and Potentially Curative Treatments
- Unlike traditional therapies that primarily manage symptoms, CRISPR-Cas9 offers a one-time treatment with the potential for permanent genetic correction, as evidenced by clinical success in diseases like SCA.
7. Proof-of-Concept for Rare and Inherited Disorders
- These applications establish a framework for treating rare genetic disorders, offering hope to patients with previously untreatable or poorly managed conditions.

5. CHALLENGES AND ETHICAL CONSIDERATIONS

5.1 Technical Challenges

- Off-Target Effects: Unintended DNA cuts can cause mutations or tumorigenesis. High-fidelity Cas9 variants and improved gRNA designs mitigate this risk.
- Delivery: Achieving efficient, tissue-specific delivery remains difficult. Viral vectors carry immunogenicity risks; non-viral systems need further optimization.

5.2 Ethical Issues

- Germline Editing: Alters future generations’ DNA, raising profound ethical, legal, and social questions, including concerns about eugenics and equity.
- Regulation: Inconsistent global policies challenge safe and equitable access to gene editing technologies, requiring coordinated international governance.

6. FUTURE PROSPECTIVES

The continued evolution of CRISPR-Cas9 technology promises to reshape the landscape of modern medicine by transitioning from experimental interventions to mainstream therapeutic strategies. While current applications have demonstrated immense potential in correcting monogenic disorders, the future holds even broader prospects:

1. Expansion to Complex and Multifactorial Diseases

Although CRISPR-Cas9 has proven highly effective in monogenic disorders, future advancements aim to tackle complex diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders. By targeting multiple genes or regulatory elements simultaneously, multiplexed CRISPR approaches may one day address polygenic disease mechanisms.

2. Next generation CRISPR Technologies

Innovations such as base editing and prime editing are expanding the CRISPR toolkit, allowing precise modifications without double-strand breaks. These tools offer increased safety and efficiency, and are expected to play a critical role in treating mutations that cannot be corrected by conventional CRISPR-Cas9.

3. Improved delivery system

A major focus of future research will be the development of non-viral delivery systems such as lipid nanoparticles, engineered exosomes, and DNA nanostructures. These delivery methods aim to reduce immunogenicity, increase targeting specificity, and improve accessibility to tissues beyond the liver and eye.

4. Wider clinical adoption and commercialization

With therapies like Casgev already receiving regulatory approval, we are entering an era where CRISPR-based treatments may soon become commercially available for a variety of genetic conditions. As more clinical trials report positive outcomes, healthcare systems must prepare for large-scale implementation.

5. Personalised gene therapy

CRISPR-Cas9 enables the customization of treatment based on individual genetic profiles, heralding a future where medicine is tailored for each patient. This could reduce trial-and-error treatment approaches and improve therapeutic efficacy across diverse populations.

6. Ethical and social readiness

As gene editing technology becomes more accessible, public dialogue and regulatory frameworks must evolve in parallel. Ethical considerations surrounding germline editing, consent, affordability, and equitable access will remain central to responsible innovation.

7. Global collaboration and policy development

The future of CRISPR will depend heavily on international cooperation among researchers, clinicians, regulatory agencies, and ethicists. Harmonized policies will be essential to ensure safety, transparency, and equitable access to gene-editing technologies worldwide.

This section ties naturally into the existing narrative of your review paper, emphasizing how the transformative potential of CRISPR-Cas9 is moving from proof-of-concept into clinical and societal reality.

8. CONCLUSION

CRISPR-Cas9 has redefined the possibilities of genetic engineering by providing a precise, efficient, and cost-effective method for editing DNA. Unlike earlier technologies such as ZFNs and TALENs, CRISPR-Cas9 utilizes a simple RNA-guided mechanism that enables targeted modifications with high accuracy. Its application in treating genetic disorders has demonstrated remarkable success, particularly in monogenic diseases like sickle cell anemia and cystic fibrosis, where gene correction or disruption can directly address the root cause of disease.

Emerging advancements such as base editing and prime editing offer even greater precision by allowing single-nucleotide changes without inducing double-strand breaks, significantly reducing off-target effects and enhancing therapeutic safety. The integration of artificial intelligence in guide RNA design further enhances specificity and streamlines the development of personalized gene therapies.

Despite these advances, several challenges must still be addressed. Delivery to specific tissues remains difficult, off-target mutations can pose safety risks, and immune responses to Cas proteins may limit efficacy. Additionally, ethical concerns surrounding germline editing, equitable access, and long-term consequences must be carefully considered and regulated through global consensus.

REFRENCES

[1] National Human Genome Research Institute. Genetic Disorders [Internet]. Genome.gov. 2020 [cited 2025 Jun 21].

[2] Feero WG, Guttmacher AE, Collins FS. Genomic medicine—an updated primer. N Engl J Med. 2010 May 27;362(21):2001–11.

[3] Nussbaum RL, McInnes RR, Willard HF. Thompson & Thompson Genetics in Medicine. 8th ed. Philadelphia: Elsevier; 2015.

[4] Cooper GM, Hausman RE. The Cell: A Molecular Approach. 6th ed. Sunderland (MA): Sinauer Associates; 2013.

[5] Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011 Nov;12(11):745–55.

[6] Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010 Sep;11(9):636–46.

[7] Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011 Mar;188(4):773–82.

[8] Joung JK, Sander JD. TALENs: a widely applicable technology for targeted genome editing. Nat Rev Mol Cell Biol. 2013 Jan;14(1):49–55.

[9] Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011 Feb;29(2):143–8.

[10] Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012 Aug 17;337(6096):816–21.

[11] Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014 Jun 5;157(6):1262–78.

[12] Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013 Feb 15;339(6121):823–6.

[13] Yin, H., & Lee, M. (2016).Genome editing using CRISPR/Cas9 technology: Challenges and new opportunities in drug discovery and genetic medicine. Pharmaceutical Research, 33(10), 2434-2445.

[14] Sander, J. D., & Joung, J. K. (2015).CRISPR-Cas9 genome editing: The end of the beginning. Genome Biology, 16(1), 1-10.

[15] Hsieh, M. M., et al. (2016). Gene therapy for sickle cell disease: Progress and challenges. Current Opinion in Hematology, 23(3), 266-274.

[16] Frangoul, H., et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 384(3), 252-260. [doi:10.1056/NEJMoa2026349]

[17] Boulad, F., et al. (2023). CRISPR-Cas9-based gene therapy for sickle cell disease: Results from clinical trials. Nature Medicine, 29(2), 261-268.

[18] Petris, M., et al. (2020). Gene editing in cystic fibrosis: A review of progress in CRISPR-Cas9-based therapies. International Journal of Molecular Sciences, 21(4), 1239.

[19] Wang, Z., et al. (2019). CRISPR-Cas9 genome editing in cystic fibrosis patient-derived cells: A new era of personalized therapy. The Lancet Respiratory Medicine, 7(5), 423-430.

[20] Hickey, M. A., & Bertram, M. (2020). CRISPR-Cas9 gene therapy for Huntington's disease: Current challenges and future directions. Human Molecular Genetics, 29(1), 11-19.

[21] Sanchez-Pernaute, R., et al. (2021). Targeted gene editing in Huntington's disease: Prospects and challenges. Trends in Neurosciences, 44(1), 41-51.

[22] Dunbar, C. E., et al. (2018). Gene editing and its application to retinal diseases: Leber congenital amaurosis and beyond. The Lancet, 391(10119), 1187-1195.

[23] Li, Q., et al. (2021). CRISPR-Cas9 mediated gene therapy for inherited retinal diseases: A critical review. International Journal of Molecular Sciences, 22(15), 7935.

[24] Gaj, T., et al. (2017). Genome-editing technologies: Principles and applications. Trends in Biotechnology, 35(3), 105-118.